Alivus Life Sciences has informed that, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, January 23, 2025, to consider and approve the Unaudited Financial Results of the Company for the third quarter and nine months ended 31st December, 2024. Further, as per the Code of Conduct for Prevention of Insider Trading and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has intimated its ‘designated persons’ regarding the closure of the Trading Window from December 31, 2024 to January 25, 2025 (both days inclusive) for the purpose of approval of Unaudited Financial Results for third quarter and nine months ended December 31, 2024.
The above information is a part of company’s filings submitted to BSE.
